SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is experiencing market pressure after its CagriSema obesity drug did not achieve non-inferiority against Eli Lilly's competitor in a recent trial, fueling community debate over its competitive standing. However, strong early demand for its oral Wegovy, coupled with recent regulatory actions against compounded GLP-1 alternatives and ongoing share buybacks, is leading many to see the current sell-off as an overreaction and a potential buying opportunity.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for BYSANTI, a new chemical entity with patent protection extending to 2044 for bipolar I disorder and schizophrenia. Community sentiment is largely bullish on significant upside potential and a possible short squeeze, though some express caution regarding a recent shelf offering and the drug's similarity to an existing therapy.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Recent positive clinical data for Arcellx's multiple myeloma CAR-T therapy, anito-cel, showcases strong efficacy and a differentiated safety profile, driving current conversation. An expanded strategic partnership and investment from Kite (Gilead), combined with the recent lifting of a partial clinical hold, reinforces market confidence and highlights the company's competitive edge in the cell therapy landscape.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Dominos Pizza is drawing attention after its Q4 earnings report showcased solid results and strategic investments, further amplified by Berkshire Hathaway's increased stake. The community is actively debating if its focus on value and digital initiatives can continue to drive market share in a competitive restaurant environment.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting stellar Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, demonstrating high efficacy and potential disease-modifying effects. This positive data, coupled with a major institutional investor significantly increasing its stake and an anticipated Investor Day, has ignited strong community discussion about its "best-in-class" potential, a potential re-rating, and a short squeeze.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is trending as the community processes its solid Q4 earnings beat against conservative 2026 guidance, alongside significant M&A activity including the Arcellx acquisition and key patent settlements for its dominant HIV franchise. Investors are also closely watching developments in its oncology pipeline, such as recent Trodelvy trial results, amid discussions about the company's long-term growth trajectory in a volatile market.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as its Mainnet recently went live and a partnership with Aplix for a Japan-regulated stablecoin was announced, alongside its inclusion in Coinbase's institutional index for perpetual futures. This has sparked a polarized community discussion, with proponents highlighting these fundamental advancements for long-term potential, while critics remain skeptical given the token's continued price performance.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as Novo Nordisk's latest obesity drug trial underperformed Eli Lilly's, reigniting community discussion that Viking's competitive dual agonist VK2735 is now a highly attractive acquisition or partnership target for pharmaceutical giants eager to capture market share.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as community debate intensifies around recent tariff rulings and new global levies, with widespread discussion focusing on their economic impact and concerns over the company's financial stability and potential dilution ahead of upcoming disclosures.

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals is trending after securing a significant patent victory for its Nuplazid drug, ensuring market exclusivity and prompting multiple analyst upgrades. The community is actively discussing the company's robust, potentially undervalued pipeline in neurological and rare diseases, balancing this against recent EU regulatory challenges for its Rett syndrome treatment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ANTIPODES PARTNERS Ltd Buys 573,065 Shares of Valaris Limited $VAL

ANTIPODES PARTNERS Ltd increased its stake in shares of Valaris Limited (NYSE:VAL - Free Report) by 8,034.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The...

Valaris Limited (VAL) Q4 Earnings and Revenues Top Estimates

Valaris (VAL) delivered earnings and revenue surprises of +54.90% and +9.44%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Valaris (NYSE:VAL) Posts Quarterly Earnings Results, Beats Estimates By $9.86 EPS

Valaris (NYSE:VAL - Get Free Report) announced its earnings results on Thursday. The company reported $10.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.40...

Valaris Limited Q4 Profit Rises

(RTTNews) - Valaris Limited (VAL) released earnings for its fourth quarter that Increased, from the same period last year...

Valaris Q4 Earnings Assessment

Valaris Reports Fourth Quarter 2025 Results

Valaris Limited (NYSE: VAL) ('Valaris' or the 'Company') today reported fourth quarter 2025 results. President and Chief Executive Officer Anton Dibowitz said, Our fourth quarter results capped...

GSA Capital Partners LLP Invests $1.21 Million in Valaris Limited $VAL

GSA Capital Partners LLP acquired a new position in Valaris Limited (NYSE:VAL - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange...

SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--VAL, VRME, TPH, and BKKT

SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--VAL, VRME, TPH, and BKKT SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--VAL, VRME, TPH, and BKKT...

Are TPH, GLDD, AIRI, VAL Obtaining Fair Deals for their Shareholders?

Are TPH, GLDD, AIRI, VAL Obtaining Fair Deals for their Shareholders? Are TPH, GLDD, AIRI, VAL Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Feb. 17, 2026 Insiders may stand to...

Stock Market Today, Feb. 17: Transocean Pares Gains After Soaring Over 100% in 6 Months

Transocean (NYSE:RIG), an offshore rig company, closed Tuesday at $6.14, down 6.12%. Today's drop could be a result of profit-taking after last week's 52-week high or a reassessment of its all-stock...

$VAL Q4 &#39;25 Earnings Results &amp; Recap

Valaris expects 2026 capital expenditures to approximate $425M to $475M, primarily for maintenance and upgrade projects, including contract-specific capital expenditures. Valaris also anticipates contributing approximately $19.2M to its pension plans in 2026.

Stocktwits

Valaris Ltd

 Q4 '25 Earnings Results & Recap

Valaris expects 2026 capital expenditures to approximate $425M to $475M, primarily for maintenance and upgrade projects, including contract-specific capital expenditures. Valaris also anticipates contributing approximately $19.2M to its pension plans in 2026.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Valaris Ltd. engages in the provision of offshore contract drilling services to the international oil and gas industry. It operates through the following segments: Floaters, Jackups, ARO, and Other. The Floaters segment includes drillships and semisubmersible rigs. The Other segment is involved in management services on rigs owned by third-parties and the activities associated with arrangements with ARO under the bareboat charter arrangements. The company was founded in 1975 and is headquartered in Hamilton, Bermuda.

Current Price	$95.75
Prev Close	$92.49
Open	$89.80
Dividend Yield	0.00%
50-Day Moving Average	$60.54
Beta	1.43
Avg. Volume	1.08M
PE Ratio	6.84

52-Week High	$96.40
52-Week Low	$27.15
Market Capitalization	$6.63B
EPS (Annual)	$13.86
Price to Book	2.73
Revenue Per Employee	$467,258.38

VAL
Valaris Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VAL News

VALValaris Ltd